Anthropic is reportedly preparing for a Nasdaq listing in November, with investors floating a valuation near $2 trillion. That figure would more than double the $965 billion post-money valuation from its May 2026 Series H round, positioning it as the largest IPO by valuation, surpassing SpaceX's reported $1.77 trillion debut earlier this year.
The headline number raises an obvious question: is it justified? Invezz posed that question, along with two others probing where the real risks lie, to three market professionals. Their answers converge on a central theme: the $2 trillion figure is not really a valuation of what Anthropic is today. It values what the market believes Anthropic's revenue mix will be over the next two to three years, and the details of that mix—not model capability—are where the argument for or against $2 trillion actually lives.
The growth the number is built on
Anthropic's annualized revenue run rate exceeded $65 billion by the end of July 2026, up from roughly $47 billion in May and about $9 billion at the end of 2025—a more than sevenfold increase in under a year. Some investors expect the run rate to reach $100 billion to $120 billion by year-end, while the company is reportedly projecting $190 billion to $200 billion in revenue in 2028.
That trajectory is central to the case for a $2 trillion price tag on a company that only recently turned adjusted operating income positive, after burning roughly $5.6 billion in cash in 2024. Kate Leaman, chief market analyst at AvaTrade, argues the growth curve is precisely why skeptics may end up wrong about the price being too rich rather than too cheap. "A $2 trillion price tag sounds enormous until you remember revenue went from a $9 billion run-rate to over $100 billion in about a year," Leaman told Invezz, referring to the projected annualized revenue trajectory rather than reported full-year revenue.
If bankers price this assuming growth decelerates hard from here, and it instead merely slows to something still absurd—say another three or four times over the next year—the IPO price will look conservative within two quarters. Nobody wanted to be the banker who put a growth rate that sounds made up into a prospectus, so they didn't, and the stock ends up playing catch-up to a number everyone privately expected.
There is a scarcity argument sitting alongside the growth argument, and Leaman thinks it matters more than investors are currently pricing in. OpenAI is not publicly tradeable. If Anthropic lists, it becomes the only large, liquid, pure-play route into frontier AI available to public market investors, a position that "does strange things to price discovery when a trade this size has nowhere else to go." Combine that with the conventional logic of hot tech IPOs, where underwriters sometimes accept a lower offer price to support a strong first-day performance rather than risk a listing that limps, and Leaman's case is that undershooting fair value is at least as plausible as overshooting it.
But she is explicit that the re-rating case depends on several conditions holding simultaneously, not just growth continuing. Revenue needs to remain enterprise- and API-driven rather than concentrated in a handful of large compute deals, because public market investors treat recurring revenue and one-off contracts very differently. Anthropic's safety spending, and partnerships built around it such as the Accenture tie-up, need to demonstrate a genuine competitive advantage rather than a cost center, evidence that enterprises are choosing Anthropic partly because of its governance story rather than in spite of it. And the macro backdrop needs to cooperate. Leaman points to the Federal Reserve's first rate hike in more than three years as a complicating factor: a market discounting future cash flows at a higher rate is "a much harder room for any re-rating story to land in, however good the growth numbers look."
Revenue quality is the whole ballgame
If Leaman's framing is about what could push the valuation higher, Veni Dhir, director of corporate venture capital at ADP, is focused on what determines whether the $2 trillion figure is actually supported by the underlying economics. Dhir shared her views in a personal capacity and not on behalf of her employer. Her starting point is that investors need to look past the headline valuation and examine what sits beneath the revenue growth.
Revenue quality—how much is durable enterprise contract spend versus usage-based API consumption that can churn—inference economics, the unit cost per task at scale which determines gross margins, and the conversion rate from enterprise pilots to production deployments. Model capability is table stakes now. The valuation math lives or dies on whether enterprise spend on Anthropic compounds like software or fluctuates like compute.
That distinction matters because Anthropic's rapid growth has been driven in significant part by usage-based AI consumption. API revenue can scale quickly as customers increase workloads, but it can also fall if enterprises reduce inference spending, switch to cheaper models or move workloads elsewhere. The more important test, Dhir argues, is whether Anthropic can turn that usage into something stickier by embedding Claude into enterprise workflows. Its push into enterprise applications, including Claude Code and agent deployments, could make the relationship harder to displace than a model API alone. "Anthropic's move into enterprise applications changes the picture in its favor," Dhir said. "Selling 'cognition' is a race to the bottom—but selling an integrated platform is a different game."
Dhir also highlights the risk of model commoditization. As open-source and rival models narrow the capability gap, pricing power could erode. The key differentiator, she argues, is distribution and workflow integration, not just the underlying model. "If Anthropic can become the default cognitive layer for enterprises, the valuation holds. If it remains a model vendor, the multiple will compress," she added.
Beyond revenue quality, analysts point to broader risks that could shape the post-IPO valuation. AI liability—lawsuits over copyright, misinformation, or harmful outputs—could create significant legal costs. Governance and safety practices, while a selling point, also impose constraints that could slow product velocity. Macro conditions, including interest rates and tech valuations, will play a role. The Fed's recent rate hike has already tightened financial conditions, making high-multiple growth stocks less attractive.
In the end, the $2 trillion question boils down to whether Anthropic can sustain its explosive growth while improving revenue quality and defending against commoditization. The market's answer will come in November, but analysts agree that the number is less about today's earnings and more about the next two to three years of execution.
This article is for informational purposes only and does not constitute financial advice.
